[Pharmaceutical interviews in onco-haematology and so-cal...

연구 요약

[Pharmaceutical interviews in onco-haematology and so-called 'natural' products: An example illustrated by cannabidiol (CBD)].

Bulletin du cancer 학술지에 발표된 이 연구는 Fleta L, Laffitte PV, Slama B 외 연구팀이 수행하였습니다.

핵심 내용

In recent years, there have been significant changes in the way cancer patients are treated. The use of oral anti-tumour therapies has accelerated outpatient treatment. In response, healthcare professionals have organised themselves to design multidisciplinary information and support pathways for the initiation of treatment. Pharmacists, as drug experts, are involved to detect and analyse drug interactions. By taking control of their illness, patients are encouraged to seek their own solutions, sometimes using complementary and alternative medicines. The use of cannabidiol in a patient suffering from chronic myeloid leukaemia in 4th line treatment illustrates this problem. High-dose cannabidiol is a strong inhibitor of cytochrome 3A4 and P-gP protein, and a weak inhibitor of cytochromes 2C19, 2B6, 2D6, 2C9, 2C8 and 1A2, as well as UGT1A9 and 2B7. Case reports complement these elements by reporting clinically significant inhibition when lower doses are used. According to current recommendations, the first four lines of treatment for chronic myeloid leukaemia are major substrates of cytochrome 3A4. There is a risk of drug-drug interaction/herb-drug interaction, even at low doses. The use of cannabidiol is strongly discouraged. Pharmacists, through their participation in multidisciplinary interviews for the initiation of oral anti-cancer therapies, contribute their expertise in the detection and analysis of potentially clinically significant interactions.

일반인을 위한 해석

이 연구는 약물 또는 영양제의 안전한 사용에 관한 과학적 근거를 제공할 수 있습니다. 다만, 개별 연구 결과만으로 일반화하기는 어려우며, 추가적인 연구가 필요할 수 있습니다.

실천 사항

• 현재 복용 중인 약물이나 영양제에 대해 궁금한 점이 있다면 담당 의사 또는 약사와 상담하시기 바랍니다
• 약물이나 영양제의 용법·용량을 임의로 변경하지 마세요
• 이상 반응이 나타나면 즉시 전문가에게 문의하세요

의사/약사의 전문적 판단을 대체하지 않습니다 (PMID: 41448973)